Monday, November 18, 2019 6:59:09 PM
Second…JJ, I am in complete agreement with your points that Elite is no longer singularly focused on the opioids business. Indeed, it is a good thing, given the socio-political-legal issues with opioids. But it does not mean there is no value in their portfolio of approved pain drugs or their ADF platform. Rather, they remain part of how Elite would be valued. Kind of like unused manufacturing plants; they still count as corporate value.
Third...I want to offer corrections and additions to my post yesterday:
To begin with, in the post I mistakenly said SunGen5 and, of course, it should be SunGen2. Sorry about that.
Also, it has been said that Elite has to share all its new revenues equally with its partners. That is incorrect. As was made obvious on the CC, Elite takes manufacturing fees for all its drugs off the top! Then, as is common among partnerships (and a little research makes clear), the developers (Elite & SunGen) get a larger percentage than the commercializer (Lannett/Glenmark); with the actual amount a matter of agreement and those specifics are not something outsiders would know.
Okay, a question for the board…On the CC, Nasrat mentioned uplisting onto the Nasdaq and the timeline seems to be traveling further into the horizon. What do you make of the ever-moving target date? (And, saying he has been lying is not a viable option!)
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2024 08:47:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • Oct 15, 2024 8:21 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
CBD Life Sciences, Inc. Announces Strategic MOU with U.S. Armed Forces for Groundbreaking Mushroom Supplement • CBDL • Oct 15, 2024 8:00 AM
HealthLynked Files Non-Provisional Patent for AI-Powered Healthcare Assistant, ARi • HLYK • Oct 15, 2024 8:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM